What is MCK stock price target for 2026?

WallStSmart's 12-month price target for McKesson Corporation is $885.45, representing 7.6% upside from the current price of $822.63.

What is MCK stock forecast?

McKesson Corporation forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is MCK undervalued based on price targets?

Our DCF intrinsic value for McKesson Corporation is $2,631.85, against a current price of $822.63. The margin of safety is 63.78%.

MCK

McKesson Corporation

NYSE: MCK · HEALTHCARE · MEDICAL DISTRIBUTION

$822.63

-1.48% today

Updated 2026-04-29

Market cap

$101.43B

P/E ratio

23.93

P/S ratio

0.26x

EPS (TTM)

$34.61

Dividend yield

0.37%

52W range

$635 – $999

Volume

0.8M

Market cap

$101.43B

P/E ratio

23.93

P/S ratio

0.26x

EPS (TTM)

$34.61

Dividend yield

0.37%

52W range

$635 – $999

Volume

0.8M

McKesson Corporation (MCK) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$822.63

Consensus

$930.00

+13.05%

2030 Target

$55,621.21

+6661.39%

DCF

$2,631.85

+63.78% MoS

Current price

$822.63

Analyst consensus

$930.00

+13.05%

2030 Target

$55,621.21

+6661.39%

Intrinsic (DCF)

$2,631.85

+63.78% MoS

13 analysts:

6 Buy2 Hold0 Sell

Management guidance

McKesson management raised FY2026 EPS guidance during Q3 earnings, demonstrating confidence in specialty drug and value-based care growth. No specific multi-year revenue targets were disclosed, but company emphasized 'strong' growth trajectory in oncology/specialty distribution and technology-enabled services through 2030.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$92,672.54

$564.0B Rev × 20x P/S

Base case (2030)

$55,621.21

$564.0B Rev × 12x P/S

Bear case (2030)

$37,051.33

$564.0B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$276.7B	$309.0B	$359.1B	$412.8B	$446.6B	$483.0B	$522.0B	$564.0B
Revenue growth	—	11.7%	16.2%	8.2%	8.2%	8.1%	8.1%	8.0%
EPS	—	$27.42	$27.46	$39.41	$44.69	$50.50	$57.00	$64.10
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$40,676.88	$44,037.14	$47,574.26	$51,465.10	$55,621.21

Catalysts & risks

Growth catalysts

+ Specialty pharma/oncology distribution growth (high-margin business)

+ Value-based care platform expansion and technology monetization

+ Biosimilar adoption acceleration and margin expansion

+ Strategic acquisitions in specialty healthcare services

+ EPS beats on strong execution (59% YoY EPS growth in TTM)

Key risks

- Drug pricing regulation and government negotiation pressure

- Margin compression from generic drug pricing deflation

- Healthcare reimbursement model disruption

- Customer consolidation reducing distributor leverage

- Specialty pharmaceutical market saturation

Methodology

McKesson Corporation's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.